Modest Effect of Impaired P-glycoprotein on the Plasma Concentrations of Fexofenadine, Quinidine, and Loperamide following Oral Administration in Collies
Authors:
- Yoshiaki KitamuraYKYoshiaki Kitamura
- Hisao KotoHKHisao Koto
- Shinobu MatsuuraSMShinobu Matsuura
- Takeshi KawabataTKTakeshi Kawabata
- Hiroshi TsuchiyaHTHiroshi Tsuchiya
- Hiroyuki KusuharaHKHiroyuki Kusuhara
- Hajime TsujimotoHTHajime Tsujimoto
- Yuichi SugiyamaYSYuichi Sugiyama
Open Access
- 1 May 2008
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 36 (5) , 807-810
Abstract
P-glycoprotein (P-gp), encoded by the multidrug resistance 1 gene (MDR1/ABCB1), exhibits very broad substrate specificity and plays important roles in drug disposition. The purpose of the present study was to examine the effect of impaired P-gp activity on the plasma pharmacokinetics of P-gp substrates in collies with or without homozygous mutant alleles producing truncated P-gp. Three therapeutic agents, fexofenadine (0.1 mg/kg), quinidine (0.1 mg/kg), and loperamide (0.01 mg/kg), were simultaneously given orally, and their plasma concentration-time profiles were determined. The plasma concentrations of these drugs tended to be higher in dogs with the homozygous mutated allele. The Cmax was 53.9 ± 13.1 and 90.7 ± 23.1 ng/ml for fexofenadine, 16.5 ± 3.4 and 20.0 ± 7.9 ng/ml for quinidine, and 80.8 ± 9.0 and 101 ± 15 pg/ml for loperamide, and the AUC0–8 was 263 ± 62 and 435 ± 95 ng·h/ml for fexofenadine, 54.5 ± 11.5 and 75.7 ± 21.8 ng·h/ml for quinidine, and 467 ± 85 and 556 ± 91 pg·h/ml for loperamide in homozygous wild-type and homozygous mutated dogs, respectively. Only the plasma concentration differences of fexofenadine at 4 to 8 h after oral administration were statistically significant. This result suggests that P-gp limits the intestinal absorption of fexofenadine in dogs. Collies with the Mdr1 mutation will be useful for examining the effect of P-gp on the oral availability of drugs.Keywords
This publication has 27 references indexed in Scilit:
- In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous SystemDrug Metabolism and Disposition, 2008
- Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux TransportersInternational Journal of Toxicology, 2006
- Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1Pharmaceutical Research, 2006
- In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]VerapamilThe Journal of Pharmacology and Experimental Therapeutics, 2006
- P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETIONDrug Metabolism and Disposition, 2005
- Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from FranceJournal of Veterinary Pharmacology and Therapeutics, 2004
- Impact of Drug Transporter Studies on Drug Discovery and DevelopmentPharmacological Reviews, 2003
- Clinical Relevance of P-Glycoprotein in Drug TherapyDrug Metabolism Reviews, 2003
- The role of intestinal P-glycoprotein in the interaction of digoxin and rifampinJournal of Clinical Investigation, 1999
- Inhibition of P-Glycoprotein–Mediated Drug TransportCirculation, 1999